Study provides valuable insights into the DCB-only strategy for left main coronary artery disease

Sanna Uskela et al., at North Karelia Central Hospital-Heart Center, Finland, conducted a retrospective single-center registry study that focused on the use of drug-coated balloon (DCB)-only strategy for treating de novo left main coronary artery disease.

Remote patient monitoring in Medicare needs more oversight: OIG

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Regulators need to boost oversight

September 27, 2024

Sarepta touts Duchenne gene therapy uptake, but warns of demand flattening before potential expanded label from FDA

Sarepta Therapeutics announced Wednesday afternoon that its Duchenne muscular dystrophy gene therapy Elevidys pulled in $200 million in its first half-year on the commercial market.

March 1, 2024

Intellia’s CRISPR-based treatment dramatically reduced patients’ swelling attacks in small trial

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks —

June 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.